Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
15,247
datasets available to search
ShareScore release 0.9.0
Dataset results
15,247 results for “Breast Cancer”
Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers
<p>This repository contains the raw IMC data of ZTMA 26 as continuation of dataset <strong>10.5281/zenodo.7494413.</strong> The zip files starting with ZTMA contain the raw IMC measurements (mcd and txt) of those parts of the TMA. The TMA measurements are split up into parts in order to avoid huge files.</p> <p>Additionally, this repository contains the metadata of the patients analyzed in this study, the panel information and the single-cell data that was extracted from the multiplexed images together with the associated metadata in SingleCellExperiment format for analysis in R.</p> <p>The analysis.zip folder contains files that were written out during the analysis according to the scripts in https://github.com/BodenmillerGroup/BC_LN_metastses.</p> <p>The single-cell and other data outputs from CellProfiler can be found in the cpout.zip file.</p> <p>The IF_whole_sections.zip file contains the IF images of the primary breast cancer sections (czi files) and the extracted single-cell data.</p>
Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers
<p>This repository contains the raw IMC data of ZTMA 21 and 25 of the matched primary breast cancer and lymph node metastasis study presented in Fischer and Jackson et al., 2023. The code that was used to process and analyze this data can be found at https://github.com/BodenmillerGroup/BC_LN_metastses.</p> <p>The zip files starting with ZTMA contain the raw IMC measurements (mcd and txt) of the respective parts of the TMA. The TMA measurements are split up into parts in order to avoid huge files.</p>
Proteome association studies of breast, prostate, ovarian, and endometrial cancers implicate plasma protein regulation in cancer susceptibility
<p>Full results datasets for Proteome association studies of breast, prostate, ovarian, and endometrial cancers implicate plasma protein regulation in cancer susceptibility:</p> <p>ALL*all_pheno.csv are TOPMed-MESA combined-ancestry models, discovery and replication cohorts</p> <p>ARIC_EA_all_pheno.csv is ARIC European-American ancestry models, discovery cohort</p> <p>ARIC*meta_all.txt is ARIC European-American ancestry models, discovery and replication cohorts, with meta-analysis of disc+rep</p>
Development of a prognostic model for early breast cancer integrating neutrophil to lymphocyte ratio and clinical-pathological characteristics
<p><strong>Abstract</strong></p> <p>Breast cancer-related inflammation is critical in tumorigenesis, cancer progression, and patient prognosis. Several inflammatory markers derived from peripheral blood cells count, such as the neutrophil-lymphocyte ratio (NLR), derived neutrophil-lymphocyte ratio (dNLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR) and systemic immune-inflammation index (SII) are considered as prognostic markers in several types of malignancy. Here, we investigate and validate a prognostic model in early breast cancer (eBC) patients to predict disease-free survival (DFS) based on readily available baseline clinicopathological prognostic factors and preoperative peripheral blood-derived indexes. We analyzed a training cohort of 710 BC patients and two external validation cohorts of 980 and 157 eBC patients, respectively, with different demographic origins. An elevated preoperative NLR is a better DFS predictor than PLR, MLR, and SII in patients with eBC. The prognostic model generated in this study was able to classify patients into three groups with different risks of relapse based on ECOG-PS, presence of comorbidities, T and N stage, PgR status, and NLR. Prognostic models derived from the combination of clinicopathological features and peripheral blood indices, such as NLR, represent attractive markers mainly because they are easily detectable and applicable in daily clinical practice. More comprehensive prospective studies are needed to unveil their actual effectiveness.</p>
Cytological and histological images of breast cancer
<p>Data set of cytological and histological images of breast cancer.</p> <p><strong>Data set structure</strong>:</p> <ol> <li>Cytological image files (size 3264x2448 px, microscope with x40 lens used). The name of each folder contains the name of the diagnosis.</li> <li>Files of histological and corresponding immunohistochemical images of breast tissue sections (size 2048x1536 px). The name of each folder contains the name of the diagnosis. Each folder contains 1 H&E histological image and 4 folders with IHC images for 4 biomarkers: estrogen receptor (ER), progesterone receptor (PR), Ki-67 Biomarker (KI67), human epidermal growth factor receptor-2 (HER2NEU).</li> </ol>
Breast Cancer Differential expressed genes from TCGA
<p>Breast cancer gene expression data from TCGA, Differential expression analysis result from DESeq2 R package comparing normal cells with breast cancer cells.</p>
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients
<p>Importance: Obesity and metabolic disorders have been associated with an increased risk of cancer and with poorer outcomes in many cohorts of breast cancer (BC) patients, with poor evidence from Mediterranean cohorts. <br> Objective: To investigate the prognostic potential of anthropometric variables, namely body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), as well as Metabolic Syndrome (MetS) and its components, in early BC patients living in a Southern Mediterranean region of Italy.<br> Design: Prospective cohort study enrolling consecutive early BC patients who were treated between January 2009 and December 2013 in Southern Italy. Median follow-up was 11.8 years and ended on June 15th 2022. Physicians who measured the study variables were blinded to patient groupings.<br> Setting: Multicenter study enrolling consecutive, early BC patients referred to specialized cancer centers.<br> Participants: A total of 955 early BC patients consecutively treated at the Istituto Nazionale dei Tumori, “G. Pascale” and at the Policlinico University Hospital “Federico II”, Naples, Italy, were enrolled. All study subjects provided written informed consent to participate. <br> Intervention(s) (for clinical trials) and exposure (for observational studies): Anthropometric measurements and indices (BMI, hip circumference and WC) were collected. MetS was defined according to NCEP-ATP III criteria. MetS components were categorized as 0, 1-2 or ≥3. <br> Main Outcomes and Measures: Overall survival and BC-specific survival. <br> Results: Mean age was 55.3 years (±12.5 years); 61% of patients were post-menopausal. At the end of follow-up, 208 (22%) patients had died, 131 (14%) of whom from BC. Obesity (BMI≥30 kg/m2) was found in 29% of enrolled patients (14% in pre- and 38% in post-menopause); 24% of patients met the criteria for a diagnosis of MetS (7% in pre- and 36% in post-menopause), whereas 1-2 MetS criteria were found in 53% of patients<br> High WC or WHR were associated with a moderately increased risk of all-cause mortality (WC ≥ 88 cm, HR=1.39, 95%CI: 1.00-1.94; WHR > 0.85, HR=1.62, 95%CI: 1.12-2.37). Furthermore, an increased risk of all-cause mortality was observed with the presence of MetS (HR=1.61, 95%CI: 1.12-2.32). An increased BC-specific mortality risk was found in obese patients (BMI≥30 kg/m2, HR=1.72, 95%CI: 1.06-2.78) and in those with WC ≥88 (HR=1.71, 95%CI: 1.12-2.61). High WHR was also associated with increased risk of BC-specific mortality, both when evaluated as a categorical variable (WHR>0.85, HR=1.80, 95%CI: 1.13-2.86) and as a continuous variable (for each 0.1-U increase in WHR, HR=1.33, 95%CI: 1.08-1.63). The presence of MetS was associated with an 81% increased risk of BC-specific mortality (HR=1.81, 95%CI: 1.51-2.85). <br> These associations varied according to menopausal status. In particular, in pre-menopausal patients higher BMI was associated with an increased risk of both all-cause and BC-specific mortality (HR=1.43 and HR=1.58, respectively). In post-menopausal women an increased risk of all-cause mortality was found only in the presence of ≥3 MetS components (HR=2.77, 95%CI: 1.09-7.06). The associations among anthropometric variables and all-cause and BC-specific mortality also varied according to BC subtype. Triple negative BC was the only disease subtype that wasn’t independently associated with BMI, WC, WHR or MetS or all-cause and BC-specific mortality.<br> Conclusions and Relevance: Central obesity and metabolic disorders result in a highly increased risk of BC death. The magnitude of this effect suggests that obesity may nullify the benefit of effective BC therapies. Active lifestyle interventions to maintain optimal body weight and to prevent MetS should be recommended for several expected beneficial effects, including a potential reduction in BC-specific mortality.</p>
Dataset: Automated quantification of stromal tumour infiltrating lymphocytes is associated with prognosis in breast cancer.
<p>Daraset of breast nulcei segmentation associated to the article "Gonzàlez-Farré, M., Gibert, J., Santiago-Díaz, P. <em>et al.</em> Automated quantification of stromal tumour infiltrating lymphocytes is associated with prognosis in breast cancer. <em>Virchows Arch</em> (2023). https://doi.org/10.1007/s00428-023-03608-4"</p>
The Magee 3 Equation Predicts Favorable Pathologic Response to Neoadjuvant Endocrine Therapy in Breast Cancer Patients
<p><strong>Supplementary Figure 1: </strong>Comparison between ROC curves of ME1, ME2, ME3, and MEm scores in a sample of breast cancer patients undergoing neoadjuvant endocrine therapy.</p> <p><strong>Supplementary Figure 2: </strong>ROC curves with their respective confidence intervals and AUC values in the sample of breast cancer patients, excluding those with clinical stage IA tumors. A: ME1. B: ME2. C: ME3. D: MEm.</p> <p><strong>Supplementary Figure 3:</strong> Comparison between ROC curves of ME1, ME2, ME3, and MEm scores in the sample of breast cancer patients undergoing neoadjuvant endocrine therapy (excluding those with clinical stage IA tumors).</p> <p> </p>
High CD8 + / FOXP3+ Ratio is Significantly Associated with Primary Endocrine Therapy Resistance Occurrence in Locally Advanced Luminal B Her-2 Negative Breast Cancer Patients
<p>High CD8 + / FOXP3+ Ratio is Significantly Associated with Primary Endocrine Therapy Resistance Occurrence in Locally Advanced Luminal B Her-2 Negative Breast Cancer Patients</p>
Supplemental Data for "Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer"
<p>Supplemental data files for Bahnassy et al, "Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer"</p>
Low-glucose eating pattern and glycemic variability in women without diabetes who are at risk for postmenopausal breast cancer
<p>This dataset contains data collected and analysed for the paper, "<strong>A low-glucose eating pattern improves glycemic variability in women without diabetes who are at risk for postmenopausal breast cancer: An exploratory analysis of an RCT"</strong></p>
Prolonged Nightly Fasting in Breast Cancer Survivors
ClinicalTrials.gov study NCT04330339. IPD Sharing: YES. Countries: 1. Publications: 1.
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
ClinicalTrials.gov study NCT01242800. IPD Sharing: YES. Countries: 5. Publications: 1.
MEtronomic TrEatment Option in Advanced bReast cAncer
ClinicalTrials.gov study NCT02954055. IPD Sharing: NO. Countries: 1. Publications: 8.
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
ClinicalTrials.gov study NCT00601900. IPD Sharing: Not stated. Countries: 2. Publications: 4.
A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.
ClinicalTrials.gov study NCT02650193. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer
ClinicalTrials.gov study NCT00693719. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Adj TC + Herceptin Early Stage Breast Cancer
ClinicalTrials.gov study NCT00493649. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
ClinicalTrials.gov study NCT01937117. IPD Sharing: NO. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.